A BetterLife Pharma is focused on developing innovative, non-hallucinogenic therapeutics aimed at addressing mental health and neurological disorders. Their lead product, BETR-001, is a second-generation derivative of lysergic acid diethylamide (LSD) that retains the therapeutic potential of traditional psychedelics while eliminating undesirable side effects such as hallucinations. This compound is designed to treat a range of psychiatric conditions, including treatment-resistant depression and post-traumatic stress disorder, as well as severe neurological issues like cluster headaches. BETR-001's non-hallucinogenic nature allows for fewer regulatory hurdles, making it a promising alternative to existing treatments.

In addition to BETR-001, BetterLife Pharma is also developing another compound, BETR-002, which is a derivative of hydrohonokiol aimed at treating benzodiazepine dependency and anxiety disorders. The company emphasizes a patient-centric approach, ensuring that their drug development processes are rooted in solid pharmacological principles. Their commitment to addressing the high unmet needs in mental health care is reflected in their ongoing research and development efforts, which include preclinical studies and plans for future clinical trials.

Canada

BetterLife Pharma is an emerging biotechnology company focused on developing and commercializing patient-friendly compounds to treat neuro-psychiatric and neurological disorders. Our vision is to take the fear out of psychedelics by producing non-hallucinogenic medicines that will be the solutions to treat the wide range of unmet mental health conditions like anxiety, depression, PTSD, & migraine

BetterLife Pharma

Company Details